Obatoclax overcomes resistance to cell death in aggressive thyroid carcinomas by countering Bcl2a1 and Mcl1 overexpression.
about
The role of BH3-mimetic drugs in the treatment of pediatric hepatoblastomaGenomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers.Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model.Obatoclax kills anaplastic thyroid cancer cells by inducing lysosome neutralization and necrosisObatoclax and LY3009120 Efficiently Overcome Vemurafenib Resistance in Differentiated Thyroid CancerModeling anaplastic thyroid carcinoma in the mouse.Anti-Metastatic Effect of Dehydrocorydaline on H1299 Non-Small Cell Lung Carcinoma Cells via Inhibition of Matrix Metalloproteinases and B Cell Lymphoma 2.Cell death induction by the BH3 mimetic GX15-070 in thyroid carcinoma cellsThe BH3 mimetic drug ABT-737 induces apoptosis and acts synergistically with chemotherapeutic drugs in thyroid carcinoma cells.SGK1 Is a Critical Component of an AKT-Independent Pathway Essential for PI3K-Mediated Tumor Development and Maintenance.
P2860
Q26827928-583A7B40-FB7D-412E-84CC-EEA230F866AFQ36618604-8A2563DC-55BD-4A79-9B12-51FE3B6D1D35Q36618887-E585DAE3-4ADB-4D4D-AEBF-1E7448DC55B6Q37376300-F8756E7B-5355-454B-A5E7-8C107E91986EQ37738239-FD0C5659-5AC3-4BC8-927B-4AEFAF1E8731Q38270915-809F328E-8ED1-4AD9-B86D-636F8359097AQ38718515-FA04F6D8-D817-45DC-8C73-FF00B571F163Q38850608-0D6CD4FD-3871-4E65-A79A-C339F514821AQ39819844-4FBB624B-FC6E-4C1B-80F6-D73A7CE00312Q47621500-60C1F93E-EDF4-4C77-838B-3C110618E0F0
P2860
Obatoclax overcomes resistance to cell death in aggressive thyroid carcinomas by countering Bcl2a1 and Mcl1 overexpression.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Obatoclax overcomes resistance ...... cl2a1 and Mcl1 overexpression.
@ast
Obatoclax overcomes resistance ...... cl2a1 and Mcl1 overexpression.
@en
Obatoclax overcomes resistance ...... cl2a1 and Mcl1 overexpression.
@nl
type
label
Obatoclax overcomes resistance ...... cl2a1 and Mcl1 overexpression.
@ast
Obatoclax overcomes resistance ...... cl2a1 and Mcl1 overexpression.
@en
Obatoclax overcomes resistance ...... cl2a1 and Mcl1 overexpression.
@nl
prefLabel
Obatoclax overcomes resistance ...... cl2a1 and Mcl1 overexpression.
@ast
Obatoclax overcomes resistance ...... cl2a1 and Mcl1 overexpression.
@en
Obatoclax overcomes resistance ...... cl2a1 and Mcl1 overexpression.
@nl
P2093
P2860
P356
P1476
Obatoclax overcomes resistance ...... Bcl2a1 and Mcl1 overexpression
@en
P2093
Devora Champa
Marika A Russo
Ronald A Ghossein
Samuel Refetoff
Xiao-Hui Liao
P2860
P304
P356
10.1530/ERC-14-0268
P577
2014-07-10T00:00:00Z